2.18
-0.24(-9.92%)
Currency In USD
Previous Close | 2.42 |
Open | 2.42 |
Day High | 2.26 |
Day Low | 2.05 |
52-Week High | 7.67 |
52-Week Low | 1.32 |
Volume | 155,996 |
Average Volume | 281,269 |
Market Cap | 24.05M |
PE | -0.47 |
EPS | -4.63 |
Moving Average 50 Days | 2.05 |
Moving Average 200 Days | 2.98 |
Change | -0.24 |
If you invested $1000 in Mangoceuticals, Inc. (MGRX) since IPO date, it would be worth $36.33 as of June 01, 2025 at a share price of $2.18. Whereas If you bought $1000 worth of Mangoceuticals, Inc. (MGRX) shares 1 year ago, it would be worth $415.24 as of June 01, 2025 at a share price of $2.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu
GlobeNewswire Inc.
May 27, 2025 1:00 PM GMT
Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platfo
Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
GlobeNewswire Inc.
Apr 25, 2025 1:00 PM GMT
DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ: MGRX) (“Mangoceuticals” or “MGRX”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform und
Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada
GlobeNewswire Inc.
Mar 25, 2025 1:00 PM GMT
Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace DALLAS, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the